Answers are grounded in this paper and cite their sources.
Review discusses advances in influenza vaccine development, including adjuvants and the pursuit of a universal vaccine.
Influenza remains a significant global health concern, prompting continual efforts to enhance vaccine efficacy and broaden protection against diverse strains. Traditional influenza vaccines primarily target strain-specific surface antigens, necessitating annual updates to match strains. Recently, use of adjuvants such as MF59 and AS03 have shown promise in augmenting immune responses, potentially reducing the need for frequent vaccine reformulation. This review explores the recent approaches in influenza vaccine development, focusing on the pursuit of a universal vaccine. Additionally, this review discusses the role of adjuvants in enhancing vaccine immunogenicity.
No takes yet. Share an insight, caveat, or question.
Vendra et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: